Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by High Net Worth Advisory Group LLC

High Net Worth Advisory Group LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,894 shares of the biopharmaceutical company’s stock after selling 125 shares during the quarter. High Net Worth Advisory Group LLC’s holdings in Gilead Sciences were worth $360,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. nVerses Capital LLC purchased a new position in Gilead Sciences in the third quarter valued at about $25,000. Valued Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the last quarter. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the second quarter worth $33,000. Finally, Quarry LP acquired a new stake in Gilead Sciences in the second quarter valued at $43,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of GILD opened at $93.07 on Monday. The firm has a market capitalization of $115.99 billion, a PE ratio of 1,034.11, a P/E/G ratio of 1.31 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average price of $91.74 and a 200 day moving average price of $84.98. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the firm posted $2.29 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 over the last 90 days. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Piper Sandler boosted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Bank of America restated a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. UBS Group lifted their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Finally, Robert W. Baird raised their price objective on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.